We prepared octreotide (OCT)-modified curcumin plus docetaxel micelles to enhance active targeting and inhibit tumor metastasis by destroying vasculogenic mimicry (VM) channels. Soluplus was applied as an amphiphilic material to form micelles via film dispersion. The cytotoxic effects, active cellular targeting, and inhibitory effects on metastasis were systematically evaluated using A549 cells, and antitumor effects were evaluated using xenograft tumor-bearing mice. assays indicated that the OCT-modified curcumin plus docetaxel micelles showed robust cytotoxicity on A549 cells and effectively inhibited VM channels and tumor metastasis. Studying the mechanism of action indicated that OCT-modified curcumin plus docetaxel micelles downregulated MMP-2 and HIF-1α. assays indicated that OCT-modified curcumin plus docetaxel micelles increased drug accumulation at tumor sites and showed obvious antitumor efficacy. The developed OCT-modified curcumin plus docetaxel micelles may offer a promising treatment strategy for non-small-cell lung cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10837450.2019.1647236 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Curcumin and Its Potential to Target the Glycolytic Behavior of Lactate-Acclimated Prostate Carcinoma Cells with Docetaxel.
Nutrients
December 2024
Department of Biochemistry, College of Medicine, Soonchunhyang University, Cheonan 31511, Republic of Korea.
Dysregulated cellular metabolism is known to be associated with drug resistance in cancer treatment. In this study, we investigated the impact of cellular adaptation to lactic acidosis on intracellular energy metabolism and sensitivity to docetaxel in prostate carcinoma (PC) cells. The effects of curcumin and the role of hexokinase 2 (HK2) in this process were also examined.
View Article and Find Full Text PDFRecent Prospectives of Cellular Signaling Role for Mammary Gland Carcinogenesis.
Anticancer Agents Med Chem
January 2025
Department of Pharmaceutical Sciences, Lucknow University, Lucknow, UP, India.
In women globally, breast cancer ranks as the second most frequent cause of cancer-related deaths, making up about 25% of female cancer cases, which is pretty standard in affluent countries. Breast cancer is divided into subtypes based on aggressive, genetic and stage. The precise cause of the problem is still unknown.
View Article and Find Full Text PDFArticle Synopsis
- - The study explored the effectiveness of combining curcumin with docetaxel for patients with advanced and metastatic breast cancer, focusing on whether this combination improved treatment response rates.
- - Conducted across multiple centers, the research included 42 patients and aimed to compare the objective response rates and other clinical outcomes between the two treatment groups but found no significant differences.
- - Ultimately, the study concluded that adding curcumin to docetaxel did not enhance efficacy and was deemed safe, leading to the decision to stop the trial due to lack of meaningful results, while suggesting further research with adjustments for more conclusive findings.
Co-Delivery of Docetaxel and Curcumin Functionalized Mixed Micelles for the Treatment of Drug-Resistant Breast Cancer by Oral Administration.
Int J Nanomedicine
August 2024
School of Pharmaceutical Sciences, Guangdong Medical University, Dongguan, 523808, People's Republic of China.
Article Synopsis
- Chemotherapeutic drugs often cause severe side effects and drug resistance, leading to a need for better delivery methods; co-delivery via nanomicelles is being explored to improve treatment.
- The study developed a new formulation of mixed micelles that combines docetaxel (DTX) and curcumin (CUR) for oral administration, which showed effective drug encapsulation, stability, and improved absorption compared to standard DTX.
- The (DTX+CUR)-loaded mixed micelles demonstrated strong anti-cancer effects in drug-resistant breast cancer cells and maintained efficacy comparable to traditional injectable treatments in animal studies.
Polymeric nanoparticles as a promising platform for treating triple-negative breast cancer: Current status and future perspectives.
Int J Pharm
October 2024
Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Science, Tehran, Iran; Primary Immunodeficiency Diseases Network (PIDNet), Universal Scientific Education and Research Network (USERN), Tehran, Iran. Electronic address:
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer that lacks expression of estrogen, progesterone, and HER2 receptor targets for therapy. Polymeric nanoparticles help address the challenges in treating TNBC by enabling tailored and targeted drug delivery. Biocompatible polymeric nanoparticles leverage enhanced tumor permeability for site-specific accumulation and ligand-mediated active targeting to boost specificity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!